Aurora Cannabis Past Earnings Performance
Past criteria checks 0/6
Aurora Cannabis has been growing earnings at an average annual rate of 59.1%, while the Pharmaceuticals industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 10% per year.
Key information
59.05%
Earnings growth rate
68.85%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.06% |
| Revenue growth rate | 10.00% |
| Return on equity | -11.45% |
| Net Margin | -18.28% |
| Next Earnings Update | 05 Aug 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jul 27
ACB: Medical Refocus And Impairment Charges Will Shape Balanced Outlook
Analysts have revised their fair value estimate for Aurora Cannabis, reducing it from CA$5.00 to CA$4.00. They cite updated assumptions regarding revenue growth, profit margins, and a slightly lower future P/E multiple.
Narrative Update • Jul 07
ACB: Medical Focus And Rescheduling Tailwinds Will Drive Future Upside Potential
Aurora Cannabis’ updated analyst price target has moved from CA$10.00 to CA$8.00 as analysts factor in lower modeled profit margins, a higher discount rate, and more conservative revenue growth assumptions, despite viewing recent partial cannabis rescheduling efforts as extremely favorable for the sector. What is in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining a plan to exit lower margin Canadian consumer and plant propagation businesses and concentrate resources on global medical cannabis, with a focus on markets such as Germany and Poland.
Narrative Update • Jun 23
ACB: Favorable Rescheduling Outlook Will Support Shift To Global Medical Focus
Analysts have revised their fair value estimate for Aurora Cannabis from CA$7.93 to CA$6.14, citing updated expectations for revenue growth, profit margins, and a higher future P/E multiple following recent research that views partial cannabis rescheduling as extremely favorable for the sector. What’s in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining plans to exit lower margin Canadian consumer and plant propagation businesses and to concentrate resources on global medical cannabis, with a focus on what the company views as higher return opportunities.Narrative Update • Jun 05
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.Narrative Update • May 09
ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.Narrative Update • Apr 20
ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.Narrative Update • Apr 05
ACB: Revised P E Assumptions And Policy Signals Will Guide Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1 as analysts factor in updated views on revenue trends, margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent research updates point to a more cautious tone around Aurora Cannabis, as analysts reassess what they are willing to pay for the stock in light of current revenue and margin expectations.Narrative Update • Mar 22
ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.Narrative Update • Mar 07
ACB: Policy Shifts And Margin Execution Will Shape Fairly Balanced Outlook
Narrative update overview The latest analyst update trims the Aurora Cannabis price target by CA$1. This reflects a shift to lower expected profit margins and a higher assumed future P/E multiple, while still leaning on prior bullish initiation as support for the longer-term story.Narrative Update • Feb 21
ACB: Policy Shift And Execution Uncertainty Will Shape Balanced Risk Profile
Aurora Cannabis: Narrative Update Analysts reduced their 12-month price target for Aurora Cannabis by CA$1. This reflects updated expectations that now assume slightly softer revenue growth, somewhat higher profit margins, and a lower future P/E multiple.Narrative Update • Feb 06
ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead
Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.Analysis Article • Nov 07
Aurora Cannabis Inc. (TSE:ACB) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...Analysis Article • Oct 03
Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 29
Aurora Cannabis Inc. (TSE:ACB) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Aurora Cannabis Inc. ( TSE:ACB ) shares have had a really impressive month, gaining 27% after a shaky period...Narrative Update • Aug 07
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92. What's in the News Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).Analysis Article • Jul 12
Aurora Cannabis Inc. (TSE:ACB) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...Analysis Article • Jun 26
Aurora Cannabis' (TSE:ACB) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Aurora Cannabis Inc. ( TSE:ACB ) recently. We did some...Analysis Article • May 23
After Leaping 29% Aurora Cannabis Inc. (TSE:ACB) Shares Are Not Flying Under The Radar
Those holding Aurora Cannabis Inc. ( TSE:ACB ) shares would be relieved that the share price has rebounded 29% in the...
New Narrative • Apr 26
EU GMP And TGA Expertise Will Expand Global Cannabis Reach
Strategic international expansion and regulatory changes in key markets could significantly boost future revenues and medical cannabis margins.Analysis Article • Feb 04
Investors Give Aurora Cannabis Inc. (TSE:ACB) Shares A 26% Hiding
Unfortunately for some shareholders, the Aurora Cannabis Inc. ( TSE:ACB ) share price has dived 26% in the last thirty...Analysis Article • Nov 22
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shareholders that were waiting for something to happen have been dealt a blow with a...Analysis Article • Aug 02
It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Key Insights Aurora Cannabis to hold its Annual General Meeting on 9th of August Salary of CA$773.6k is part of CEO...Analysis Article • Jun 27
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Analysis Article • Feb 15
Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem
We didn't see Aurora Cannabis Inc.'s ( TSE:ACB ) stock surge when it reported robust earnings recently. We decided to...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Aurora Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 321 | -59 | 175 | 4 |
| 31 Dec 25 | 373 | -84 | 178 | 4 |
| 30 Sep 25 | 367 | -57 | 177 | 3 |
| 30 Jun 25 | 358 | -3 | 171 | 4 |
| 31 Mar 25 | 289 | 27 | 164 | 4 |
| 31 Dec 24 | 320 | 15 | 164 | 4 |
| 30 Sep 24 | 296 | -29 | 162 | 3 |
| 30 Jun 24 | 278 | -30 | 160 | 3 |
| 31 Mar 24 | 270 | -53 | 156 | 4 |
| 31 Dec 23 | 266 | -108 | 181 | 4 |
| 30 Sep 23 | 262 | -153 | 174 | 5 |
| 30 Jun 23 | 248 | -195 | 167 | 5 |
| 31 Mar 23 | 224 | -793 | 170 | 6 |
| 31 Dec 22 | 212 | -1,748 | 163 | 8 |
| 30 Sep 22 | 210 | -1,757 | 180 | 8 |
| 30 Jun 22 | 221 | -1,718 | 176 | 10 |
| 31 Mar 22 | 226 | -1,233 | 185 | 11 |
| 31 Dec 21 | 231 | -381 | 189 | 12 |
| 30 Sep 21 | 238 | -607 | 188 | 13 |
| 30 Jun 21 | 245 | -692 | 195 | 11 |
| 31 Mar 21 | 257 | -2,387 | 206 | 16 |
| 31 Dec 20 | 275 | -2,359 | 241 | 18 |
| 30 Sep 20 | 263 | -3,342 | 300 | 23 |
| 30 Jun 20 | 269 | -3,231 | 346 | 26 |
| 31 Mar 20 | 299 | -1,405 | 372 | 24 |
| 31 Dec 19 | 291 | -1,430 | 397 | 22 |
| 30 Sep 19 | 290 | -385 | 376 | 17 |
| 30 Jun 19 | 246 | -294 | 365 | 15 |
| 31 Mar 19 | 168 | -211 | 327 | 10 |
| 31 Dec 18 | 119 | -72 | 253 | 7 |
| 30 Sep 18 | 77 | 174 | 187 | 5 |
| 30 Jun 18 | 55 | 72 | 110 | 2 |
| 31 Mar 18 | 42 | -13 | 69 | 1 |
| 31 Dec 17 | 31 | 7 | 45 | 0 |
| 30 Sep 17 | 23 | -4 | 31 | 0 |
| 30 Jun 17 | 18 | -13 | 25 | 0 |
| 31 Mar 17 | 13 | -16 | 19 | 0 |
| 31 Dec 16 | 8 | -13 | 13 | 0 |
| 30 Sep 16 | 5 | -10 | 8 | 1 |
| 30 Jun 16 | 1 | -6 | 6 | 1 |
| 31 Mar 16 | 0 | 0 | 5 | 1 |
| 31 Dec 15 | 0 | -3 | 4 | 1 |
Quality Earnings: ACB is currently unprofitable.
Growing Profit Margin: ACB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACB is unprofitable, but has reduced losses over the past 5 years at a rate of 59.1% per year.
Accelerating Growth: Unable to compare ACB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (96.7%).
Return on Equity
High ROE: ACB has a negative Return on Equity (-11.45%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/31 22:30 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurora Cannabis Inc. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Etienne Ricard | BMO Capital Markets Equity Research |
| Heather Balsky | BofA Global Research |